Exedra

Exela Pharma Sciences develops, manufactures, and markets both proprietary and generic sterile injectable pharmaceuticals. The company also provides contract manufacturing services through its CDMO business unit. Its FDA-inspected facilities have capacity for over one hundred million sterilized units per year. Products are developed via NDA, ANDA, or 505(b)(2) regulatory pathways with an emphasis on high-barrier-to-entry generics that improve patient/provider experience by enhancing safety profiles or administration convenience. The company has played a significant role in revitalizing its local economy through job creation in North Carolina.